Maravai LifeSciences Holdings, Inc. (MRVI) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 7 recommend buying, 6 recommend holding, and 1 recommend selling.
The analyst consensus price target for MRVI is $4.50, representing a +37.2% upside from the current price of $3.28. Price targets range from a low of $4.50 to a high of $4.50.
